PMID- 32620958
OWN - NLM
STAT- MEDLINE
DCOM- 20210531
LR  - 20210531
IS  - 1535-2900 (Electronic)
IS  - 1079-2082 (Linking)
VI  - 77
IP  - 17
DP  - 2020 Aug 20
TI  - Novel mobile application for direct communication between pharmacists and 
      patients treated with oral antineoplastic agents.
PG  - 1393-1402
LID - 10.1093/ajhp/zxaa144 [doi]
AB  - PURPOSE: Initial experience with use of a smartphone application to enhance 
      communication with and home monitoring of hematology/oncology patients under 
      treatment with oral antineoplastic agents (OAAs) is described. SUMMARY: Broad use 
      of OAAs is changing the landscape of hematology/oncology patient care, with this 
      form of therapy giving patients greater autonomy but also raising concerns about 
      correct OAA administration and management of adverse effects (AEs) or 
      interactions. Information and communication technologies, specifically mobile 
      health technologies, are ideal tools in this new environment. A multidisciplinary 
      team at a large hospital in Spain developed a smartphone application for patients 
      receiving OAA therapy that consists of 5 modules or functionalities: (1) a 
      treatment agenda, or electronic journal of patient activity, including medication 
      use; (2) a treatment record; (3) continuous recording of vital signs (blood 
      pressure and temperature), health-related quality of life, and AEs, with 
      management of AEs based on an algorithm that displays different recommendations 
      according to AE severity; (4) 2-way messaging capability; and (5) information and 
      links to websites of interest. From June through November 2017, 37 patients 
      downloaded and used the application. About two-thirds (68%) of the patients sent 
      a total of 182 messages to the pharmacist on duty; 58% of the patients registered 
      at least 1 AE. The mean time of registration of the first AE after initiation of 
      OAA therapy was 8 days. As a result of patient use of the application, 2 
      emergency room visits were avoided and 3 patients were referred to a general 
      practitioner. CONCLUSION: The application has allowed real-time monitoring of 
      patients treated with OAAs. This new patient-pharmacist communication channel has 
      facilitated the early detection of AEs, contributing to the safety of treatment 
      and patient satisfaction with healthcare.
CI  - (c) American Society of Health-System Pharmacists 2020. All rights reserved. For 
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Collado-Borrell, Roberto
AU  - Collado-Borrell R
AD  - Pharmacy Department, Hospital General Universitario Gregorio Maranon, Instituto 
      de Investigacion Sanitaria Gregorio Maranon (IiSGM), Madrid, Spain.
FAU - Escudero-Vilaplana, Vicente
AU  - Escudero-Vilaplana V
AD  - Pharmacy Department, Hospital General Universitario Gregorio Maranon, Instituto 
      de Investigacion Sanitaria Gregorio Maranon (IiSGM), Madrid, Spain.
FAU - Ribed, Almudena
AU  - Ribed A
AD  - Pharmacy Department, Hospital General Universitario Gregorio Maranon, Instituto 
      de Investigacion Sanitaria Gregorio Maranon (IiSGM), Madrid, Spain.
FAU - Jimenez, Rosa Romero
AU  - Jimenez RR
AD  - Pharmacy Department, Hospital General Universitario Gregorio Maranon, Instituto 
      de Investigacion Sanitaria Gregorio Maranon (IiSGM), Madrid, Spain.
FAU - Peinado, Irene Iglesias
AU  - Peinado II
AD  - College of Pharmacy, Complutense University of Madrid, Madrid, Spain.
FAU - Herranz-Alonso, Ana
AU  - Herranz-Alonso A
AD  - Pharmacy Department, Hospital General Universitario Gregorio Maranon, Instituto 
      de Investigacion Sanitaria Gregorio Maranon (IiSGM), Madrid, Spain.
FAU - Sanjurjo-Saez, Maria
AU  - Sanjurjo-Saez M
AD  - Pharmacy Department, Hospital General Universitario Gregorio Maranon, Instituto 
      de Investigacion Sanitaria Gregorio Maranon (IiSGM), Madrid, Spain.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Communication
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mobile Applications
MH  - Patient Satisfaction
MH  - Pharmacists/*organization & administration
MH  - Pharmacy Service, Hospital/organization & administration
MH  - *Professional-Patient Relations
MH  - Quality of Life
MH  - Smartphone
MH  - Spain
MH  - Young Adult
OTO - NOTNLM
OT  - e-OncoSalud
OT  - hematology/oncology patient
OT  - home monitoring
OT  - oral antineoplastic agents
OT  - safety
OT  - smartphone application
EDAT- 2020/07/06 06:00
MHDA- 2021/06/01 06:00
CRDT- 2020/07/05 06:00
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2021/06/01 06:00 [medline]
PHST- 2020/07/05 06:00 [entrez]
AID - 5867286 [pii]
AID - 10.1093/ajhp/zxaa144 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2020 Aug 20;77(17):1393-1402. doi: 10.1093/ajhp/zxaa144.